A comprehensive analysis of clinical and preclinical data reveals that GLP-1 receptor agonists, previously suspected of increasing cancer risk, are generally safe and may even reduce the incidence of certain cancers through improved…

A comprehensive analysis of clinical and preclinical data reveals that GLP-1 receptor agonists, previously suspected of increasing cancer risk, are generally safe and may even reduce the incidence of certain cancers through improved…